A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
试验速览
- 阶段
- 不适用
- 入组人数
- 254
- 试验地点
- 1
- 主要终点
- Assess the efficacy of raltegravir in study participants by measuring CD4 count and viral load
研究概览
简要总结
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services. It has become a widely used antiretroviral therapy option for HIV infected patients. It provides good tolerability and a favorable lipid profile for patients when compared to some other antiretroviral treatment options. Little data is reported about efficacy in a minority patient population. Moreover, data in an indigent minority population in the United States has not been aggregated before. Therefore this study will investigate the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health Center.
- •Minority women -Black/African American, Hispanic/Latino
排除标准
- 未提供
研究组 & 干预措施
women that picked up raltegravir 2013
minority women that picked up raltegravir at Thomas street Health Center 2013
干预措施: raltegravir (Drug)
结局指标
主要结局
Assess the efficacy of raltegravir in study participants by measuring CD4 count and viral load
时间窗: 24 weeks of therapy
次要结局
- Capture data on concomitant conditions that may have led to participants switching to raltegravir from medical records (eg. Diabetes mellitus)(24 weeks of therapy)
- Assess tolerability of raltegravir by capturing symptoms(24 weeks of therapy)
研究者
Tanvir K. Bell, MD
Associate Professor of Medicine
The University of Texas Health Science Center, Houston